Showing 1591-1600 of 1690 results for "".
- Intensive Care Unit Stays Doubles Risk of Dementiahttps://practicalneurology.com/news/having-a-stay-in-an-intensive-care-unit-correlated-with-doubled-incidence-of-dementia/2469976/In a study presented at the Alzheimer's Association International Congress 2022 (AAIC2022), a correlation was found between stays in intensive care units (ICUs) and dementia. After adjusting for age, sex, education, and racialized identity, individuals who had a stay in t
- Herpes Zoster May Reduce Dementia Riskhttps://practicalneurology.com/news/herpes-zoster-may-reduce-dementia-risk/2469928/Despite scientific speculation that inflammation may increase risk of dementia, a new study published in Neurology has found that herpes zoster is not associated with an increased risk of dementia. “As a person’s age increases, so does their risk of dementia,
- Lecanemab for Potential Treatment of Early Alzheimer’s Disease Fully Submitted to FDAhttps://practicalneurology.com/news/lecanemab-for-potential-treatment-of-early-alzheimers-disease-fully-submitted-to-fda/2469907/A rolling submission to the Food and Drug Administration (FDA) for approval lecanemab (BAN2401; Eisai, Tokyo, Japan) for treatment of mild cognitive impairment associated with Alzheimer disease (AD) or mild AD has been completed. Submission for approval via the accelerated pathway
- Cerebrospinal Fluid Diagnostic Test for Synucleinopathies Now Availablehttps://practicalneurology.com/news/cerebrospinal-fluid-diagnostic-test-for-synucleinopathies-now-available/2469865/A new, first-in-class laboratory test (Syntap; Amprion, San Diego, CA) has become available that provides accurate measurement of misfolded α-synuclein aggregates in cerebrospinal fluid (CSF). The test is certified by Clinical Laboratory and Improvement Amendments (CLIA) and Clinical Associ
- FDA Approves Ganaxolone for Treatment CDKL5 Deficiency Disorder, a Rare Genetic Epilepsyhttps://practicalneurology.com/news/fda-approves-ganaxolone-for-treatment-cdkl5-deficiency-disorder-a-rare-genetic-epilepsy/2469857/The Food and Drug Administration (FDA) has approved ganaxolone (Ztalmy; Marinus Pharmaceuticals, Radnor, PA) for treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency, a rare genetic epilepsy. Ganaxolone is an oral suspension and was approved for individuals, age
- Women With Migraine May Have a Higher Risk of Pregnancy Complicationshttps://practicalneurology.com/news/women-with-migraine-may-have-a-higher-risk-of-pregnancy-complications/2469844/According to a preliminary study, women with migraine may have a higher risk of pregnancy complications (eg, gestational hypertension, preterm delivery, and preeclampsia). Among women with migraine, the presence of aura was associated with a 51% higher risk of preeclampsia compared with a 29% hig
- Validation of Artificial Intelligence-Assisted Imaging for Strokehttps://practicalneurology.com/news/validation-of-artificial-intelligence-assisted-imaging-for-stroke/2469822/Data from several new studies presented at the American Heart Association International Stroke Conference validate the sensitivity and specificity of an artificial intelligence-assisted imaging system (Viz LVO and Viz LCH; Viz.ai, San Francisco, CA) for evaluation of stroke in real-world settings
- Relative Ischemic Lesion Growth Decreased More with nVNS for Treatment of Acute Strokehttps://practicalneurology.com/news/relative-ischemic-lesion-growth-decreased-more-with-nvns-for-treatment-of-acute-stroke/2469819/Data presented at the American Heart Associations’ 2022 International Stroke Conference suggests safety and feasibility of noninvasive vagus nerve stimulation (nVNS)(electroCore, Rockaway, NJ) in the acute treatment of stroke. The randomized sham-controlled study TR-VENUS (
- FDA Accepts Priority Review Application for Fenfluramine for Lennox-Gastaut Seizureshttps://practicalneurology.com/news/fda-accepts-priority-review-application-for-fenfluramine-for-lennox-gastaut-seizures/2469762/The Food and Drug Administration (FDA) has accepted for filing and granted priority review to a supplemental New Drug Application (sNDA) for the use of fenfluramine (Fintepla; Zogenix, Emeryville, CA) for seizures associated with Lennox-Gastaut syndrome (LGS). The FDA granted priority review with
- National Treatment and Diagnostic Alzheimer Disease Registry Announcedhttps://practicalneurology.com/news/national-treatment-and-diagnostic-alzheimer-disease-registry-announced/2469739/Launch of a new national registry to collect real-world evidence on the diagnosis, treatment, and outcomes in Alzheimer disease (AD) has been announce. The registry is a joint initiative of The Alzheimer’s Association; the American College of Radiology; the American Society of Neuroradiolog